These data have prompted efforts to develop an N-myristoyltransferase inhibitor as a means to therapeutically target the FGF10/FGFR/Src signaling axis in cancer (French et al., 2004; Thinon et al., 2014; Kim et al., 2017). The gene discussed is FGF10; the disease is cancer.